Literature DB >> 18194842

New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy.

Juan J Cruz1, Alberto Ocaña, Miguel Navarro, Elvira Del Barco, Emilio Fonseca.   

Abstract

Advanced locoregional disease is the most frequent clinical situation in Head and Neck cancer. The standard of care for most clinicians is a multidisciplinary treatment with concomitant chemotherapy plus radiotherapy (CRT). However, retrospective studies have shown that in patients treated with CRT there was a relative increase in systemic relapse due to a lack of systemic control. For this reason a renewed interest has appeared for the incorporation of induction chemotherapy in the treatment of locally advanced Head and Neck Cancer. Furthermore new combination regimens with taxanes have shown to be more active than the classical cisplatin and 5-fluorouracil induction regimen. For these reasons ongoing trials are comparing induction chemotherapy followed by chemoradiotherapy with chemoradiotherapy alone. In this review, we will discuss the currently available data that support the design of these clinical trials as well as the future role of new agents in this clinical situation.

Entities:  

Mesh:

Year:  2008        PMID: 18194842     DOI: 10.1016/j.ctrv.2007.12.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  2 in total

1.  Phenethyl isothiocyanate enhances TRAIL-induced apoptosis in oral cancer cells and xenografts.

Authors:  Cheng-Chang Yeh; Hui-Hsin Ko; Yu-Ping Hsieh; King-Jean Wu; Mark Yen-Ping Kuo; Yi-Ting Deng
Journal:  Clin Oral Investig       Date:  2016-01-29       Impact factor: 3.573

2.  Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.

Authors:  Yan Ma; Yuhua Wang; Zhenghong Xu; Yongjun Wang; John K Fallon; Feng Liu
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.